Strides Pharma Science Ltd on Tuesday said it will immediately launch its generic Molnupiravir, indicated for high-risk adult patients with COVID-19, in India under the brand Stripiravir. The company has received Emergency Use Authorisation from the Drugs Controller General of India (DCGI) to launch Molnupiravir 200mg, an oral medication for COVID-19, in India.In a statement, Strides said it will “immediately launch Molnupiravir in India under its brand Stripiravir”.The company is commercialising the product with a group integrated supply chain for Active Pharmaceutical Ingredients and solid oral dosage from its large-scale WHO Pre-Qualified (PQ) manufacturing capacities, it added.
“We are delighted to receive the DCGI approval for launching Molnupiravir, which has shown promising results in several clinical studies. The product provides therapeutic benefit to the patients with mild-to-moderate COVID symptoms and can be administered at home,” Strides Pharma Science Ltd Managing Director and CEO R Ananthanarayanan said.
With the emergence of the new variants, he said, “we believe Molnupiravir will benefit the broad population, which could be at risk due to COVID-19. We remain committed in our fight against this global pandemic”.Indian authorities granted restricted emergency use approval to Molnupiravir for the treatment of adult patients with COVID-19 and who have a high risk of progression of the disease.
Strides said Molnupiravir has been granted approval by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a safe and effective medication for patients with mild to moderate cases of COVID-19. It also recently received the USFDA’s Emergency Use Authorisation
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022